Scientists have been selected to present a poster on an open label study of the effectiveness of ketamine in adults with Major Depressive Disorder at Imminent Risk of Suicide (MDD) at the start of this year's suicide conference in New York.
Source: prnewswire.comPublished on 2021-10-01
Related news
- 21Vianet Wins 5A Green Data Center Ratings and Further Promotes Carbon Reduction
- Who is Giving ? Who is Getting ? Giving Trends in the Pandemic Era
- Seelos Therapeutics to Present a Poster on SLS - 002 at the 2021 IASR / AFSP International Summit on Suicide Research
- Seelos Therapeutics Receives a Research and Development Grant from The Michael J . Fox Foundation for Parkinson Research for SLS - 004
- Seelos Therapeutics Announces Completion of Open - Label Patient Enrollment of Proof of Concept Study of SLS - 002 for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder
- Acceldata open sources data platform and data observability libraries
- Study links unemployment to increase in violence during early pandemic
- Ionis announces new donidalorsen data and presentations at the 2023 American Academy of Allergy , Asthma & Immunology Annual Meeting